Multiple Myeloma: International Myeloma Foundation : •about myeloma    : more advanced : KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial

Contact Us

We are international

Donate

newly diagnosed?

10 steps to better care®

caregivers

frequently asked questions

other resources of interest

step 1: get the correct diagnosis

step 2: tests you really need

step 3: Initial treatment options

step 4: supportive care

step 5: transplant

step 6: response assessment.

step 7: consolidation/maintenance

the basics

KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial

Cyrille Hulin, MD
Itergroupe Francophone du Myélome

	06.29.07
Audio of Dr. Hulin's presentation. Be the first to comment	print share \| related articles